5,7-dihydroxy-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine | 214707-01-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5,7-dihydroxy-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine
• 英文别名: 6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diol；6-(2,4,6-Trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine-5,7-diol；7-hydroxy-6-(2,4,6-trifluorophenyl)-4H-[1,2,4]triazolo[1,5-a]pyrimidin-5-one
• CAS: 214707-01-4
• 化学式: C₁₁H₅F₃N₄O₂
• 分子量: 282.182
• InChiKey: VWLLJGCBAIPGFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  5,7-dihydroxy-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine 在 三氯氧磷 作用下， 25.0~140.0 ℃ 、260.0 kPa 条件下， 以93.6%的产率得到5,7-dichloro-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  Method for production of aryl-substituted annelated pyrimidines

  摘要：

  本发明涉及一种制备芳基取代的融合嘧啶的方法，其通式为(I)，其中L1至L5为H、卤素、CN、NO2、C1-C4烷基、C1-C4卤代烷基、C1-C4烷氧基、C1-C4卤代烷氧基等；Y1至Y3为C—RY或N；RY为H或可选取代的C1-C4烷基，或两个相邻的RY共同形成一个环；X为OH、Cl或Br；包括以下步骤：（i）在合适的碱存在下，将2-苯基丙二酸酯与化合物(III)或其互变异构体反应，反应过程中生成的化学式为R—OH的醇在减压下不断从反应混合物中除去；从而得到通式(I)或其盐的化合物，其中X为OH；如果通式(I)中的X为氯或溴，则进行以下步骤(ii)：用卤化试剂反应通式(I)的化合物或其盐。

  公开号：

  US20100087640A1
• 作为产物：
  描述：

  3-氨基-1,2,4-三氮唑 、 2,4,6-三氟苯基丙二酸二乙酯 在 三正丁胺 作用下， 25.0~150.0 ℃ 、80.0 kPa 条件下， 以97%的产率得到5,7-dihydroxy-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]pyrimidine
  参考文献：
  名称：

  Method for production of aryl-substituted annelated pyrimidines

  摘要：

  本发明涉及一种制备芳基取代的融合嘧啶的方法，其通式为(I)，其中L1至L5为H、卤素、CN、NO2、C1-C4烷基、C1-C4卤代烷基、C1-C4烷氧基、C1-C4卤代烷氧基等；Y1至Y3为C—RY或N；RY为H或可选取代的C1-C4烷基，或两个相邻的RY共同形成一个环；X为OH、Cl或Br；包括以下步骤：（i）在合适的碱存在下，将2-苯基丙二酸酯与化合物(III)或其互变异构体反应，反应过程中生成的化学式为R—OH的醇在减压下不断从反应混合物中除去；从而得到通式(I)或其盐的化合物，其中X为OH；如果通式(I)中的X为氯或溴，则进行以下步骤(ii)：用卤化试剂反应通式(I)的化合物或其盐。

  公开号：

  US20100087640A1

文献信息

• [EN] 6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS<br/>[FR] 6-[(SUBSTITUTEES)PHENYL]TRIAZOLOPYRIMIDINES UTILISEES EN TANT QU'AGENT ANTICANCEREUX
  申请人：WYETH CORP

  公开号：WO2005030775A1

  公开（公告）日：2005-04-07

  This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compounds or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof. The present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.

  本发明涉及某些6-[(取代)苯基]三唑吡咯嗪化合物或其药用盐，以及含有所述化合物或其药用盐的组合物，其中所述化合物是对哺乳动物中的癌症具有治疗作用的抗癌剂。本发明还涉及一种治疗或抑制哺乳动物中癌症肿瘤细胞及相关疾病生长的方法，并进一步提供了一种治疗或预防表达多药耐药性（MDR）或因MDR而具有耐药性的癌症肿瘤的方法，该方法包括向该哺乳动物施用所述化合物或其药用盐的有效量。本发明涉及一种通过促进微管聚合来治疗或抑制哺乳动物中癌症肿瘤细胞及相关疾病生长的方法，该方法包括向该哺乳动物施用所述化合物及其药用盐的有效量。
• Method for Production of Substituted Phenylmalonate Esters, Novel Phenylmalonate Esters and Use Thereof
  申请人：Gotz Norbert

  公开号：US20080200675A1

  公开（公告）日：2008-08-21

  A process for preparing substituted phenylmalonic esters of the formula in which R is alkyl and Q is halogen, alkyl, alkoxy, haloalkyl or haloalkoxy and the index m is an integer from 1 to 5, where the groups Q can be identical or different if the index m is greater than 1, comprising steps A), B) and C): A) reaction of compounds of the formula II, in which the variables are as defined for formula I to give compounds of the formula III, B) conversion of the compounds of the formula III into ketals of the formula IV in which R′ is C 1 -C 4 -alkyl or benzyl, C) hydrolysis of the compounds of the formula IV to give compounds of the formula I; novel phenylmalonic ester derivatives, and their use as intermediates.

  一种制备公式中的取代苯丙二酸酯的方法其中R为烷基，Q为卤素，烷基，烷氧基，卤代烷基或卤代烷氧基，指数m为1到5的整数，其中如果指数m大于1，则基团Q可以相同或不同，包括步骤A），B）和C）：A）化合物II的反应，其中变量如公式I中所定义，得到化合物III的反应，B）将化合物III转化为公式IV的酮缩物，其中R′为C1-C4-烷基或苄基，C）水解化合物IV以得到公式I的化合物；新型苯丙二酸酯衍生物及其用作中间体。
• Process for the preparation of tubulin inhibitors
  申请人：Wu Yanzhong

  公开号：US20050124635A1

  公开（公告）日：2005-06-09

  The present invention provides a process for the preparation of 6-[(substituted)phenyl]-triazolopyrimidine dicarboxylic acid salt and as a hydrated salt having the structural formula (I) wherein: R 1 is CF 3 or C 2 F 5 ; R 2 is H or C 1 -C 3 alkyl; n is an integer of 2, 3, or 4; X is Cl or Br; R 3 and R 4 are each independently H or C 1 -C 3 alkyl; or R 3 and R 4 when optionally taken together with the nitrogen atom to which each is attached form a 4 to 6 membered saturated heterocyclic ring having 1-2 nitrogen atoms and 0-1 oxygen atoms or 0-1 sulfur atoms, and optionally substituted with R 5 ; R 5 is C 1 -C 3 alkyl; wherein the dotted line is an optional bond.

  本发明提供了一种制备6-[(取代)苯基]-三唑吡咯嗪二羧酸盐和作为水合盐的过程，其具有结构式(I)，其中：R1为CF3或C2F5；R2为H或C1-C3烷基；n为2、3或4的整数；X为Cl或Br；R3和R4分别独立地为H或C1-C3烷基；或者当R3和R4与各自连接的氮原子一起形成1-2个氮原子和0-1个氧原子或0-1个硫原子的4至6个成员饱和杂环环，并可选地取代R5；R5为C1-C3烷基；其中虚线表示可选键。
• 6-[(Substituted)phenyl]triazolopyrimidines as anticancer agents
  申请人：Zhang Nan

  公开号：US20050090508A1

  公开（公告）日：2005-04-28

  This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compounds or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof. The present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.

  本发明涉及某些6-[(取代)苯基]三唑嘧啶化合物或其药学上可接受的盐，以及含有该化合物或其药学上可接受的盐的组合物，其中该化合物是对哺乳动物癌症治疗有用的抗癌剂。本发明还涉及一种用于治疗或抑制哺乳动物中癌细胞肿瘤的生长和相关疾病的方法，并进一步提供了一种用于治疗或预防因多药耐药（MDR）而表达多重药物抗性的癌性肿瘤的方法，该方法包括向所述哺乳动物中需要的部位注射所述化合物或其药学上可接受的盐的有效量。本发明还涉及一种通过促进微管聚合来治疗或抑制哺乳动物中癌细胞肿瘤的生长和相关疾病的方法，该方法包括向所述哺乳动物中注射所述化合物及其药学上可接受的盐的有效量。
• 7-(R)-aminotriazolopyrimidines, their preparation and their use for controlling phytopathogenic fungi
  申请人：Blasco I. Jordi Tormo

  公开号：US20060135538A1

  公开（公告）日：2006-06-22

  7-(R)-Aminotriazolopyrimidines of the formula I where the substituents and the index are as defined below: R 1 is hydrogen or methyl; R 2 is methyl; R 3 is C 2 -C 1 o-alkyl, C 1 -C 4 -alkoxymethyl, C 3 -C 1 o-cycloalkyl; R 4 is halogen, Cl-C 4 -alkyl, C 1 -C 4 -haloalkyl or Cl-C 4 -alkoxy; n is a number from 1 to 5; Y is halogen, cyano, Cl-C 4 -alkyl or C l -C 4 -alkoxy; where * is a center of chirality in the R configuration, processes for preparing these compounds, compositions comprising them and their use for controlling harmful fungi are described.

  公式I中的7-(R)-氨基三嗪嘧啶化合物，其中取代基和指数的定义如下：R1为氢或甲基；R2为甲基；R3为C2-C10烷基、C1-C4-烷氧甲基、C3-C10环烷基；R4为卤素、Cl-C4-烷基、C1-C4-卤代烷基或Cl-C4-烷氧基；n为1至5的数字；Y为卤素、氰基、Cl-C4-烷基或Cl-C4-烷氧基；其中*为R构型的手性中心，描述了制备这些化合物的方法、包含它们的组合物以及它们用于控制有害真菌的用途。